Health technology company BioWave Corp reported on Tuesday the availability of the new US FDA cleared, over the counter version of its popular, non-opioid, patented, pain relief technology, the BioWaveGO.
The company said the BioWave products are Professional Athlete proven and US Military trusted and is currently used by most NFL, NBA, NHL, and MLB teams, 160+ college programmes, over 80 VA hospitals, as well as by pain doctors nationally.
BioWave is available in a wearable, non-prescription strength to help anyone in acute or chronic pain lead a fuller and active pain-free life. BioWave technology has been proven effective, significantly reducing pain from just one 30-minute treatment and comes with a 30-day money back guarantee. The US FDA-cleared, high-frequency neurostimulation technology delivers soothing therapeutic signals through the skin into deep tissue, blocking pain signals at the source, added the company.
In conjunction, the company stated the development of the new BioWaveGO OTC product is the natural evolution of a patented neurostimulator pain relief technology that was developed over more than ten years. BioWaveGo is available for purchase on the BioWave website and under Federal Supply Schedule contract number V797D-70205.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT